| 131I | Iodine-131 |
| 177Lu | Lutetium-177 |
| 18F | Fluorine-18 |
| 18F-FAMT | 18F-L-3-fluoro-α-methyl-tyrosine |
| 18F-FBPA | 18F-fluoro-boronophenylalanine |
| [18F]FSPG | (4S)-4-(3-fluoropropyl)-L-glutamate |
| 211At | Astatine-211 |
| 213Bi | Bismuth-213 |
| 223Ra | Radium-223 |
| 225Ac | Actinium-225 |
| AA | Amino acid |
| AAMP | 2-[211At]AAMP (LAT1-targeted analogue) |
| AAMT | 211At-labeled α-methyl-L-tyrosine |
| ABCB1 | ATP-binding cassette subfamily B member 1 (P-glycoprotein) |
| ABCG2 | ATP-binding cassette subfamily G member 2 (BCRP) |
| ADC | Antibody–drug conjugate |
| ADCC | Antibody-dependent cellular cytotoxicity |
| AHR | Aryl hydrocarbon receptor |
| AKT | Protein kinase B |
| ALK | Anaplastic lymphoma kinase |
| ASCT2 | Alanine-serine-cysteine transporter 2 (SLC1A5) |
| ATF4 | Activating transcription factor 4 |
| ATR | Ataxia telangiectasia and Rad3-related protein |
| B2M | Beta-2-microglobulin |
| BCH | 2-Aminobicyclo[2.2.1]heptane-2-carboxylic acid |
| BenSer | Benzylserine |
| CD98hc/4F2hc | Heavy chain of CD98 (SLC3A2) |
| CDC | Complement-dependent cytotoxicity |
| CHK1 | Checkpoint kinase 1 |
| CSC | Cancer stem cell |
| CYP | Cytochrome P450 |
| DDR | DNA damage response |
| DM1 | Maytansinoid DM1 |
| DNA | Deoxyribonucleic acid |
| DSB(s) | Double-strand break(s) |
| DTP | Drug-tolerant persister(s) |
| EBRT | External-beam radiotherapy |
| EGFR | Epidermal growth factor receptor |
| EMT | Epithelial–mesenchymal transition |
| ERBB3 | Erb-B2 receptor tyrosine kinase 3 (HER3) |
| ERK | Extracellular signal-regulated kinase |
| EZH2 | Enhancer of zeste homolog 2 |
| F(ab′)2 | Antibody fragment F(ab′)2 |
| FIN(s) | Ferroptosis inducer(s) |
| GPX4 | Glutathione peroxidase 4 |
| GMP | Good Manufacturing Practice |
| GSH | Glutathione |
| GATOR2 | GAP activity toward Rags complex 2 |
| HIF-1 | Hypoxia-inducible factor 1 |
| HIF-2α | Hypoxia-inducible factor 2 alpha |
| HLA-I | Human leukocyte antigen class I |
| HMGB1 | High mobility group box 1 |
| HR | Homologous recombination |
| ICI(s) | Immune checkpoint inhibitor(s) |
| ICD | Immunogenic cell death |
| IDO1 | Indoleamine 2,3-dioxygenase 1 |
| IEDDA | Inverse electron-demand Diels–Alder reaction |
| iRGD | Internalizing the RGD peptide |
| JPH203 | Nanvuranlat (LAT1 inhibitor) |
| KEAP1 | Kelch-like ECH-associated protein 1 |
| KRASG12C | KRAS p.G12C mutation |
| LAG-3 | Lymphocyte-activation gene 3 |
| LAT1 | L-type amino acid transporter 1 (SLC7A5) |
| LET | Linear energy transfer |
| MABG | meta-Astatobenzylguanidine |
| MAPK | Mitogen-activated protein kinase |
| mAb | Monoclonal antibody |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MeV | Mega-electron volt |
| MDSC(s) | Myeloid-derived suppressor cell(s) |
| MMAE | Monomethyl auristatin E |
| mTOR | Mechanistic target of rapamycin |
| mTORC1 | mTOR complex 1 |
| NaAt | Sodium astatide ([211At]NaAt) |
| NAD(P)H | Nicotinamide adenine dinucleotide (phosphate), reduced form |
| NFE2L2 | Nuclear factor erythroid-derived 2-like 2 |
| NHEJ | Non-homologous end-joining |
| NRF2 | Nuclear factor erythroid 2-related factor 2 |
| NSCLC | Non-small cell lung cancer |
| OER | Oxygen-enhancement ratio |
| OS | Overall survival |
| PD-L1 | Programmed death-ligand 1 |
| PEG | Polyethylene glycol |
| PET | Positron emission tomography |
| PI3K | Phosphoinositide 3-kinase |
| PK | Pharmacokinetics |
| PLGA | Poly(lactic-co-glycolic acid) |
| PBD | Pyrrolobenzodiazepine |
| PRIT | Pretargeted radioimmunotherapy |
| PSMA | Prostate-specific membrane antigen |
| Rag GTPases | Ras-related GTP-binding proteins A–D |
| RGD | Arg-Gly-Asp peptide |
| ROS | Reactive oxygen species |
| ROS1 | c-ros oncogene 1 (receptor tyrosine kinase) |
| RT | Radiotherapy |
| SAB | N-succinimidyl astatobenzoate |
| SAGMB | Guanidinomethyl-substituted succinimidyl astatobenzoate |
| SBRT | Stereotactic body radiotherapy |
| SLC1A5 | Solute carrier family one member 5 (ASCT2) |
| SLC3A2 | Solute carrier family three member 2 (CD98hc/4F2hc) |
| SLC7A5 | Solute carrier family seven member 5 (LAT1) |
| SLC7A11 | Solute carrier family seven member 11 (xCT) |
| SLC38A2 (SNAT2) | Sodium-coupled neutral amino acid transporter 2 |
| SLC43A2 | Solute carrier family 43 member 2 |
| SNAT2 | See SLC38A2 |
| TAZ | WW domain-containing transcription regulator 1 |
| TIGIT | T cell immunoreceptor with Ig and ITIM domains |
| TIM-3 | T cell immunoglobulin and mucin domain 3 |
| TKI(s) | Tyrosine kinase inhibitor(s) |
| TME | Tumor microenvironment |
| Treg(s) | Regulatory T cell(s) |
| TRT | Targeted radionuclide therapy |
| V-9302 | Small-molecule glutamine transport inhibitor |
| VISTA | V-domain Ig suppressor of T-cell activation |
| WEE1 | WEE1 G2 checkpoint kinase |
| xCT | Cystine/glutamate antiporter (SLC7A11) |
| YAP | Yes-associated protein |